进展期胃癌淋巴结清扫研究进展

doi:10.11904/j.issn.1002-3070.2019.01.014

实用肿瘤学杂志 ›› 2019, Vol. 33 ›› Issue (1): 78-81.doi: 10.11904/j.issn.1002-3070.2019.01.014

进展期胃癌淋巴结清扫研究进展

张宝¹ 综述, 郑志超² 校审

1.辽宁省肿瘤医院,中国医科大学肿瘤医院,中国医科大学(沈阳 110122);
2.辽宁省肿瘤医院,中国医科大学肿瘤医院胃外科

收稿日期:2018-06-23 出版日期:2019-02-28 发布日期:2019-02-13
通讯作者: 郑志超,E-mail:drzhengzhichao1@126.com
作者简介:张宝,男,(1991-),硕士研究生,从事胃部肿瘤的诊断及治疗的研究。

Research progress in lymph nodes dissection of advanced gastric cancer

ZHANG Bao¹, ZHENG Zhichao²

1.Liaoning Cancer Hospital & Institute,Cancer Hospital of China Medical University,China Medical University,Shenyang 110122,China;
2.Cancer Hospital of China Medical University,Liaoning Cancer Hospital & Institute

Received:2018-06-23 Online:2019-02-28 Published:2019-02-13

摘要/Abstract

摘要： 标准胃癌D2根治术已成为全球共识。但是,对于特定患者选择性地进行扩大淋巴结清扫(D2+)手术可能提高其生存期。D2联合No.8p﹑No.10﹑No.12b﹑No.13﹑No.14v﹑No.16a2/b1组淋巴结清扫,可能会导致手术相关并发症的发生。因此我们建议,特定患者可以适当进行D2+根治术,但应该在有足够临床经验的医学治疗中心进行。

关键词: 进展期胃癌, No.10, No.12, No.14v, No.16a2/b1

Abstract: Standard gastric cancer D2 radical surgery has become a global consensus.However,selective augmentation of lymph node dissection(D2+)surgery for a particular patient may increase their survival.D2 combined with No.8p,No.10,No.12b,No.13,No.14v,No.16a2/b1 lymph node dissection may lead to corresponding surgery-related complications.Therefore,we recommend that patients should be performed appropriate D2+ radical surgery at a medical treatment center with sufficient clinical experience.

Key words: Advanced gastric cancer, No.10, No.12, No.14v, No16a2/b1

中图分类号:

R735.2

张宝综述, 郑志超校审. 进展期胃癌淋巴结清扫研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 78-81.

ZHANG Bao, ZHENG Zhichao. Research progress in lymph nodes dissection of advanced gastric cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 78-81.

参考文献

1 符涛,季加孚.胃癌诊疗的热点和问题[J].中国肿瘤临床,2016,43(1):2-5.
2 Costamagna G,Cesaro P.Early gastric cancer:detection and endoscopic treatment[J].Ann Ital Chir,2012,83(3):183-191.
3 Basaran H,Koca T,Cerkesli AK,et al.Treatment outcomes and survival study of gastric cancer patients:a retrospective analysis in an endemic region[J].Asian Pac J Cancer Prev,2015,16(5):2055-2060.
4 Galizia G,Lieto E,Auricchio A,et al.Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer:A western experience[J].PLoS One,2017,12(4):e0173619.
5 Sano T,Coit DG,Kim HH,et al.Proposal of a new stage grouping of gastric cancer for TNM classification:International Gastric Cancer Association staging project[J].Gastric Cancer,2016,20(2):1-9.
6 Mahul BAMD,Frederick LGMD,Stephen BEMD,et al.The Eighth Edition AJCC Cancer Staging Manual:Continuing to build a bridge from a population‐based to a more "personalized" approach to cancer staging[J].CA Cancer J Clin,2017,67(2):93-99.
7 Association JGC.Japanese gastric cancer treatment guidelines 2010(ver.3)[J].Gastric Cancer,2017,62(2):113-123.
8 Marrelli D,De Franco L,Iudici L,et al.Lymphadenectomy:state of the art[J].Transl Gastroenterol Hepatol,2017,2:3.
9 Tóth D,Plósz J,Török M.Clinical significance of lymphadenectomy in patients with gastric cancer[J].World J Gastrointest Oncol,2016,8(2):136-146.
10 中华人民共和国卫生部医政司.胃癌诊疗规范(2011年版)[J].中国医学前沿杂志(电子版),2012,4(5):62-71.
11 Biondi A,D′Ugo D,Cananzi FC,et al.Does a minimum number of 16 retrieved nodes affect survival in curatively resected gastric cancer?[J].Eur J Surg Oncol,2015,41(6):779-786.
12 陈路川,魏晟宏,叶再生,等.进展期胃癌No.8p淋巴结转移的危险因素及预后分析[J].中华胃肠外科杂志,2017,20(2):218-223.
13 武卫鹏,邓靖宇,梁寒,等.远端胃癌淋巴结转移规律及临床意义[J].中国肿瘤临床,2015,42(18):906-911.
14 Sasada S,Ninomiya M,Nishizaki M,et al.Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer[J].Anticancer Res,2009,29(8):3347-3351.
15 Zhu G,Sun Z,Wang Z,et al.Splenic hilar lymph node metastasis independently predicts poor survival for patients with gastric cancers in the upper and/or the middle third of the stomach[J].J Surg Oncol,2012,105(8):786-792.
16 Hyung WJ,Lim JS,Song J,et al.Laparoscopic spleen-preserving splenic hilar lymph node dissection during total gastrectomy for gastric cancer[J].J Am Coll Surg,2008,207(2):e6.
17 Hong ZL,Chen QY,Zheng CH,et al.A preoperative scoring system to predict the risk of No.10 lymph node metastasis for advanced upper gastric cancer:a large case report based on a single-center study[J].Oncotarget,2017,8(45):80050-80060.
18 Huang CM,Chen QY,Lin JX,et al.Huang＇s three-step maneuver for laparoscopic spleen-preserving No.10 lymph node dissection for advanced proximal gastric cancer[J].Chin J Cancer Res,2014,26(2):208-210.
19 Feng JF,Huang Y,Liu J,et al.Risk factors for No.12p and No.12b lymph node metastases in advanced gastric cancer in China[J].Ups J Med Sci,2013,118(1):9-15.
20 You X,Wang Y,Li W,et al.Clinical significance of No.12 lymph node dissection for advanced gastric cancer[J].Zhonghua Wei Chang Wai Ke Za Zhi,2017,20(3):283-288.
21 Songun I,Putter H,Kranenbarg EM,et al.Surgical treatment of gastric cancer:15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J].Lancet Oncol,2010,11(5):404-405.
22 Association JGC.Japanese gastric cancer treatment guidelines 2014(ver.4)[J].Gastric Cancer,2017,20(1):1-19.
23 Kumagai K,Sano T,Hiki N,et al.Survival benefit of “D2-plus” gastrectomy in gastric cancer patients with duodenal invasion[J].Gastric Cancer,2017,21(20):1-7.
24 Eom BW,Joo J,Park B,et al.Improved survival after adding dissection of the superior mesenteric vein lymph node(14 v)to standard D2 gastrectomy for advanced distal gastric cancer[J].Surgery,2014,156(3):737-738.
25 陈若华,汪灏,王萌,等.胃癌肠系膜上静脉旁淋巴结转移的影响因素分析[J].中华胃肠外科杂志,2014,17(2):155-157.
26 Sano T,Sasako M,Yamamoto S,et al.Gastric cancer surgery:morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501[J].J Clin Oncol,2004,22(14):2767-2773.
27 Sasako M,Sano T,Yamamoto S,et al.D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer[J].N Engl J Med,2008,359(5):453.
28 Kaito A,Kinoshita T,Tokunaga M,et al.Prognostic factors and recurrence pattern of far-advanced gastric cancer with pathologically-positive para-aortic lymph nodes[J].Anticancer Res,2017,37(7):3685-3692.
29 Zhang Y,Tian S.Does D2 plus para-aortic nodal dissection surgery offer a better survival outcome compared to D2 surgery only for gastric cancer consistently? A definite result based on a hospital population of nearly two decades[J].Scand J Surg,2013,102(4):251-257.
30 Tsuburaya A,Mizusawa J,Tanaka Y,et al.Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis[J].Br J Surg,2014,101(6):653-660.
31 Wang Y,Yu YY,Li W,et al.A phase II trial of Xeloda and oxaliplatin(XELOX)neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis[J].Cancer Chemother Pharmacol,2014,73(6):1155-1161.
32 梁月祥,梁寒,丁学伟,等.N3期胃癌D2联合腹主动脉旁淋巴结清扫对患者生存预后的影响[J].中华外科杂志,2013,51(12):1071-1076.
33 梁寒.局部进展期胃癌的精准淋巴结清扫[J].中华胃肠外科杂志,2016,19(2):138-143.

[1]	张锡,陈力,薛英威. 外周血中CEA和CA19-9的表达水平在进展期胃癌中的预后价值[J]. 实用肿瘤学杂志, 2017, 31(4): 342-347.
[2]	陈力, 张玉新, 左艳娇, 马菲, 宋洪江, 薛英威. SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较[J]. 实用肿瘤学杂志, 2017, 31(1): 23-30.
[3]	许亚晔, 陈学发, 李秀娟, 周振寿. 螺旋CT扫描对进展期胃癌浸润深度的研究[J]. 实用肿瘤学杂志, 2012, 26(2): 146-149.
[4]	邱岩;罗娅红;于韬;李森. 应用低场MRI平扫评价进展期胃癌的胃壁及胃周浸润[J]. 实用肿瘤学杂志, 2008, 22(01): 32-34.
[5]	谷小虎;赵宜良. FOLFOX方案行胃癌新辅助化疗38例疗效观察[J]. 实用肿瘤学杂志, 2006, 20(06): 538-540.
[6]	王莉;俞春江;耿敬姝. 缺氧诱导因子-1α、VEGF在进展期胃癌中的表达及意义[J]. 实用肿瘤学杂志, 2005, 19(05): 337-340.
[7]	邱岩;于韬;罗娅红. 螺旋CT增强扫描对进展期胃癌胃周淋巴结转移的研究[J]. 实用肿瘤学杂志, 2004, 18(06): 449-451.
[8]	胡民主. 进展期胃癌术中及术后两周腹腔抗癌药物温热治疗分析[J]. 实用肿瘤学杂志, 2003, 17(02): 156-157.
[9]	张小龙;姜立华. 33例进展期胃癌D4手术的应用分析[J]. 实用肿瘤学杂志, 2002, 16(01): 34-35.
[10]	杨宇红;赵娟. 进展期胃癌组织氧化与抗氧化代谢特点的初步分析[J]. 实用肿瘤学杂志, 2001, 15(03): 171-172.

进展期胃癌淋巴结清扫研究进展

Research progress in lymph nodes dissection of advanced gastric cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价